- ASSOCIATE PROFESSOR Medicine, Hematology and Medical Oncology
MD, UCLA School of Medicine
Residency, Internal Medicine
Columbia University Medical Center
Fellowship, Hematology & Onc.
University of California - San Francisco
Dr. Chari served as an Assistant Professor of Medicine at the Columbia University College of Physicians and Surgeons, where he founded and developed the multiple myeloma program and was also a member of the stem cell transplant program. He then joined the nationally renowned myeloma program at St Vincents Comprehensive Cancer Center prior to its transition to the Mount Sinai Medical Center.
He is the principal investigator on several clinical trials. He has also given numerous lectures on plasma cell disorders and has served as a moderator and abstract reviewer for the American Society of Hematology in this field. He is the Mt Sinai representative on the Multiple Myeloma Research Consortium.
Dr. Chari has a longstanding dedication to research. He was awarded two research fellowships from the National Institutes of Health as an undergraduate at Stanford University, where he was elected to Phi Beta Kappa.
He recieved a Howard Hughes Medical Institute Fellowship during medical school, and an Amgen Research Award during hematology/oncology fellowship. The culmination of his research efforts have been a number of articles, book chapters, and abstracts.
Dr. Chari has also been recognized for excellence in the education of physicians in training. At the Columbia University College of Physicians and Surgeons, he was chosen by the residents in internal medicine to receive the Best Junior Faculty Teacher Award in 2008 and also selected to receive the Ewig Teaching Award by the Department of Internal Medicine.
- Phase I/Ib Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients with Normal Renal Function or Severe Renal Impairment
- A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
- An Open-label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma
- A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor, with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
- A Multicenter Phase 1/2b of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
- A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
- Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
- A Phase 1 Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
- A Phase II , Single-Center, Open Label study of Oral Panobinostat (LBH589) when administered in combination with Lenalidomide and weekly Dexamethasone in patients with multiple myeloma
- An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Chari during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited ); Novartis
Scientific Advisory Board:
- Array BioPharma; Celgene Corporation; Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited ); Novartis; Onyx Pharmaceuticals, Inc.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Celgene Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place, Box 1185
New York, NY 10029
1470 Madison Avenue
New York, NY 10029